Should all dialysis patients with hepatitis C be treated? If so, before or after kidney transplantation?

Michel Jadoul, Paul Martin

Research output: Contribution to journalEditorial

5 Citations (Scopus)

Abstract

HCV infection by genotype 1 and 4 can now be cured in close to 100% of patients with stage 4 or 5 CKD, including dialysis patients. Several regimens are available, all interferon-free and given for only 12 weeks. Thus unless life expectancy is short, HCV infection should be treated. The optimal timing of antiviral treatment will be dependent on several parameters: the possibility of being transplanted rapidly (either with a HCV+ graft or from a living donor) calls for treatment after transplantation. On the contrary, severe liver fibrosis, especially with portal hypertension calls for immediate treatment of HCV. Finally specific HCV genotype also impacts the treatment decision as genotypes 2,3,5 and 6 currently can be treated more easily after restoration of kidney function rather than in the presence of severe CKD, although this is anticipated to change soon once newer pangenotypic regimens are licensed.

Original languageEnglish (US)
Pages (from-to)395-397
Number of pages3
JournalSeminars in Dialysis
Volume30
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Hepatitis C
Kidney Transplantation
Dialysis
Genotype
Living Donors
Portal Hypertension
Therapeutics
Life Expectancy
Infection
Liver Cirrhosis
Interferons
Antiviral Agents
Transplantation
Transplants
Kidney

ASJC Scopus subject areas

  • Nephrology

Cite this

Should all dialysis patients with hepatitis C be treated? If so, before or after kidney transplantation? / Jadoul, Michel; Martin, Paul.

In: Seminars in Dialysis, Vol. 30, No. 5, 01.09.2017, p. 395-397.

Research output: Contribution to journalEditorial

@article{ca7f5e3ea33d4ac992b83ec3a26b10f5,
title = "Should all dialysis patients with hepatitis C be treated? If so, before or after kidney transplantation?",
abstract = "HCV infection by genotype 1 and 4 can now be cured in close to 100{\%} of patients with stage 4 or 5 CKD, including dialysis patients. Several regimens are available, all interferon-free and given for only 12 weeks. Thus unless life expectancy is short, HCV infection should be treated. The optimal timing of antiviral treatment will be dependent on several parameters: the possibility of being transplanted rapidly (either with a HCV+ graft or from a living donor) calls for treatment after transplantation. On the contrary, severe liver fibrosis, especially with portal hypertension calls for immediate treatment of HCV. Finally specific HCV genotype also impacts the treatment decision as genotypes 2,3,5 and 6 currently can be treated more easily after restoration of kidney function rather than in the presence of severe CKD, although this is anticipated to change soon once newer pangenotypic regimens are licensed.",
author = "Michel Jadoul and Paul Martin",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/sdi.12640",
language = "English (US)",
volume = "30",
pages = "395--397",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Should all dialysis patients with hepatitis C be treated? If so, before or after kidney transplantation?

AU - Jadoul, Michel

AU - Martin, Paul

PY - 2017/9/1

Y1 - 2017/9/1

N2 - HCV infection by genotype 1 and 4 can now be cured in close to 100% of patients with stage 4 or 5 CKD, including dialysis patients. Several regimens are available, all interferon-free and given for only 12 weeks. Thus unless life expectancy is short, HCV infection should be treated. The optimal timing of antiviral treatment will be dependent on several parameters: the possibility of being transplanted rapidly (either with a HCV+ graft or from a living donor) calls for treatment after transplantation. On the contrary, severe liver fibrosis, especially with portal hypertension calls for immediate treatment of HCV. Finally specific HCV genotype also impacts the treatment decision as genotypes 2,3,5 and 6 currently can be treated more easily after restoration of kidney function rather than in the presence of severe CKD, although this is anticipated to change soon once newer pangenotypic regimens are licensed.

AB - HCV infection by genotype 1 and 4 can now be cured in close to 100% of patients with stage 4 or 5 CKD, including dialysis patients. Several regimens are available, all interferon-free and given for only 12 weeks. Thus unless life expectancy is short, HCV infection should be treated. The optimal timing of antiviral treatment will be dependent on several parameters: the possibility of being transplanted rapidly (either with a HCV+ graft or from a living donor) calls for treatment after transplantation. On the contrary, severe liver fibrosis, especially with portal hypertension calls for immediate treatment of HCV. Finally specific HCV genotype also impacts the treatment decision as genotypes 2,3,5 and 6 currently can be treated more easily after restoration of kidney function rather than in the presence of severe CKD, although this is anticipated to change soon once newer pangenotypic regimens are licensed.

UR - http://www.scopus.com/inward/record.url?scp=85028775128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028775128&partnerID=8YFLogxK

U2 - 10.1111/sdi.12640

DO - 10.1111/sdi.12640

M3 - Editorial

C2 - 28786139

AN - SCOPUS:85028775128

VL - 30

SP - 395

EP - 397

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 5

ER -